x
Filter:
Filters applied
- ISCT Publications
- Hill, Andrew FRemove Hill, Andrew F filter
- Borràs, Francesc ERemove Borràs, Francesc E filter
Publication Date
Please choose a date range between 2020 and 2020.
Author
- Anderson, Johnathon D1
- Bussolati, Benedetta1
- Börger, Verena1
- Carter, David RF1
- Dominici, Massimo1
- Falcón-Pérez, Juan M1
- Giebel, Bernd1
- Gimona, Mario1
- Hoffman, Andrew M1
- Levine, Bruce L1
- Lim, Rebecca1
- Lim, Sai Kiang1
- Lötvall, Jan1
- Mitsialis, S Alex1
- Monguió-Tortajada, Marta1
- Muraca, Maurizio1
- Nieuwland, Rienk1
- Nowocin, Anna1
- O'Driscoll, Lorraine1
- Ortiz, Luis A1
- Phinney, Donald G1
- Reischl, Ilona1
- Rohde, Eva1
ISCT Publications
1 Results
- Short Communication
International Society for Extracellular Vesicles and International Society for Cell and Gene Therapy statement on extracellular vesicles from mesenchymal stromal cells and other cells: considerations for potential therapeutic agents to suppress coronavirus disease-19
CytotherapyVol. 22Issue 9p482–485Published online: May 16, 2020- Verena Börger
- Daniel J. Weiss
- Johnathon D. Anderson
- Francesc E. Borràs
- Benedetta Bussolati
- David R.F. Carter
- and others
Cited in Scopus: 69STATEMENT: The International Society for Cellular and Gene Therapies (ISCT) and the International Society for Extracellular Vesicles (ISEV) recognize the potential of extracellular vesicles (EVs, including exosomes) from mesenchymal stromal cells (MSCs) and possibly other cell sources as treatments for COVID-19. Research and trials in this area are encouraged. However, ISEV and ISCT do not currently endorse the use of EVs or exosomes for any purpose in COVID-19, including but not limited to reducing cytokine storm, exerting regenerative effects or delivering drugs, pending the generation of appropriate manufacturing and quality control provisions, pre-clinical safety and efficacy data, rational clinical trial design and proper regulatory oversight.
